Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04636723
Other study ID # IRB #202009
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 22, 2021
Est. completion date December 7, 2021

Study information

Verified date January 2023
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the present research protocol is to investigate and identify translocator protein 18kDa, MRI DTI, and EEG/ERPs, markers of Chronic Systemic Symptoms (CSS).


Description:

In 2016, there were an estimated 15.5 million cancer survivors in the US, with a forecasted 20.3 million by 2026. Three percent of those survivors were treated for Head and neck cancers (HNC). This number is expected to rise due to increased long-term survival in patients with HPV associated oropharyngeal cancer. Increasing survivorship has generated a surge of interest in late effects of HNC therapy. Studies to date have largely focused on chronic effects stemming from local tissue damage. Recent data suggests that late systemic effects may be equally problematic. Chronic systemic symptoms (CSS) persist far longer than previously considered and are the source of significant function loss and detriment to quality of life. CSS include fatigue, neurocognitive dysfunction, centralized pain, mood disorders, sleep disturbances, and hypothalamic dysfunction manifested as thermal discomfort or hyperhidrosis. Systemic symptoms occur in clusters resulting in a heightened clinical impact. As with other critical illnesses, the trajectory of recovery from the systemic symptoms from cancer treatment is varied. Some patients will recover to baseline quickly post treatment while others display CSS that persist or worsen over time resulting in functional deficits, frailty, and an early aging phenotype which may impact survival. Survivors exhibiting a "slow burn" trajectory as manifested by persistent systemic symptom burden and worsening function over time, require extensive on-going long-term management. These patients often fail to return to work or previously held family roles. CSS may therefore be associated with greater economic cost than the initial treatment. Work that spans a wide array of inflammatory disease processes (such as fibromyalgia, chronic fatigue syndrome, irritable bowel, etc.) demonstrate the presence of somatic, affective, and cognitive symptoms. Neuroinflammation is hypothesized to be the underlying cause of these symptoms and their manifestations. More specifically, peripheral injury/trauma/cancer release inflammatory mediators that activate glial components of peripheral and central cellular circuitry causing inflammation of the CNS. However, the concept that CSS is underlined by neuroinflammation is largely theoretical from disparate and indirect evidence. A gap in the evidence base suggests direct investigation of neuroinflammation in CSS patients in capturing a mechanistic marker is urgently needed in order to (1) present CSS as a diagnostic entity, (2) fully understand its neurobiological mechanism, and (3) test/develop appropriate treatments.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 7, 2021
Est. primary completion date December 7, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility - Inclusion Criteria for HNC patients: - Age = 21 - HNC of larynx, pharynx, oral cavity paranasal sinus, salivary gland, or unknown primary - Any histology of any epithelial origin - Completed therapy a minimum of 3 months prior to study entry - At least two systemic symptoms on the VHNSS-GSS subscale - Able to speak English to understand instructions and be able to provide informed consent - Exclusion Criteria for HNC patients: - History of neurodegenerative disease, unrelated to cancer history/treatment - Alcohol/substance abuse/dependence within the last 6 months - Current or previous co-morbid bipolar disorder-, psychosis-, obsessive compulsive disorder-, eating disorders-, personality disorders-, - Neurological disorders unrelated to cancer and its treatment (e.g. ADHD, ASDs, epilepsy) - Learning difficulties. - Inclusion Criteria for healthy controls: - Age = 21 - Able to speak English to understand instructions and be able to provide informed consent - Exclusion Criteria for healthy controls: - History of HNC of larynx, pharynx, oral cavity paranasal sinus, salivary gland, or unknown primary - Alcohol/substance abuse/dependence within the last 6 months - Current or previous co-morbid bipolar disorder-, psychosis-, obsessive compulsive disorder-, eating disorders-, personality disorders-, - Neurological disorders (e.g. ADHD, ASDs, epilepsy) - Learning difficulties.

Study Design


Locations

Country Name City State
United States Vanderbilt University Medical Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Clinical Measure: Vanderbilt Head and Neck Symptom Survey (VHNSS) version 2.0 plus general symptom survey (GSS) Validated tool to measure physical symptom burden and functional deficits related to head/neck cancer and its treatment. 12 months
Other Clinical Measure: Neurotoxicity Rating Scale (NRS) 37 item tool examining neurocognitive symptoms associated with neurotoxicity of medical treatment. 12 months
Other Clinical Measure: Central Sensitivity Inventory (CSI) Two-part survey consisting of 35 questions. Part A aims to identify frequency of experienced systemic symptoms. Part B determines previous diagnosis of Central Sensitivity Syndromes or related disorders. 12 months
Other Clinical Measure: Pain Inventory (PI) Diagram in which patients document specific areas of pain in the body, and rate pain intensity on a scale 1-10 in the past 3 months (i.e. with scores 3+ constituting chronic pain). 12 months
Other Clinical Measure: Patient Reported Outcomes Measurement Information System (PROMIS-29) assesses 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, participation in social roles/activities) using 5-point Likert scale, across 29-items. 12 months
Other Clinical Measure: • Behavior Rating Inventory of Executive Function - Adult version (BRIEF-A) Measures nine non-overlapping theoretically and empirically derived clinical domains: Inhibit, Self-Monitor, Plan/Organize, Shift, Initiate, Task Monitor, Emotional Control, Working Memory, and organization of Materials. 12 months
Primary Positron Emission Tomography (PET) Centralized Microglial Activation measured via mitochondrial translocator protein 18kDa (TSPO). 12 months
Secondary EEG/ERP concomitant to working memory neurobehavioral task Cognitive function as recommended by the International Cognition and Cancer Task Force (ICCTF) 12 months
Secondary EEG/ERP concomitant to sustained attention neurobehavioral task Cognitive function as recommended by the International Cognition and Cancer Task Force (ICCTF) 12 months
Secondary Diffusion Tensor Imaging (DTI) Diffusion coefficients as measure of cellular inflammation 12 months
Secondary Peripheral Cytokine and Chemokine Inflammation Blood marker Interleukin-6 (IL-6) 12 months
Secondary Peripheral Cytokine and Chemokine Inflammation Blood marker C reactive protein (CRP) 12 months
Secondary Peripheral Cytokine and Chemokine Inflammation Blood marker nuclear factor (NF)-kB transcription factor 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients